February 10, 2016
The FDA has put the Phase 3 trials of Pacritinib on full clinical hold, noting overall survival results. CTI BioPharma Corp. has withdrawn their NDA (New Drug Application). Click here to read more.
From their press release, CTI BioPharma states that they are working with the FDA to understand the issues and remains comitted to seeing the drug approved.
Patient Power also put out a video featuring Dr. Ruben Mesa speaking about this issue: http://www.patientpower.info/video/breaking-news-what-the-fda-hold-on-the-pacritinib-trial-means